Skip to main content

Drug Interactions between Cytosar and Oforta

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

cytarabine fludarabine

Applies to: Cytosar (cytarabine) and Oforta (fludarabine)

ADJUST DOSING INTERVAL: Cytarabine can impair the metabolism of fludarabine. The mechanism is inhibition of phosphorylation of arabinosyl-2-fluoroadenine. As a result, plasma levels of the active fludarabine triphosphate, F-ara-ATP, are decreased. Also, F-ara-ATP can potentiate deoxycytidine kinase--that is, the phosphorylation of cytarabine. As a result, plasma levels of the active cytarabine triphosphate, ara-CTP, are increased.

MANAGEMENT: It has been suggested that cytarabine be given as a relatively short-term infusion (two to four hours) following fludarabine to minimize metabolic interference with the subsequent fludarabine dose and to maximize ara-CTP synthesis.

References

  1. Kemena A, Gandhi V, Shewach DS, Keating M, Plunkett W "Inhibition of fludarabine metabolism by arabinosylcytosine during therapy." Cancer Chemother Pharmacol 31 (1992): 193-9
  2. Gandhi V, Estey E, Keating MJ, Plunkett W "Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy." J Clin Oncol 11 (1993): 116-24

Switch to consumer interaction data

Drug and food interactions

No alcohol/food interactions were found. However, this does not necessarily mean no interactions exist. Always consult your healthcare provider.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer